Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | OGA | O60502 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL807737 | 0.81 | HRH4 (0.59) | HRH3HRH4KDM4EALDH1A1MAPT | |
| SCHEMBL30579439 | 0.78 | SMN1; SMN2 (0.50) | AKT1HRH4 | |
| SCHEMBL807296 | 0.78 | SMN1; SMN2 (0.50) | AKT1HRH4 | |
| SCHEMBL19004851 | 0.78 | AKT1 (0.47) | AKT1HRH4 | |
| SCHEMBL5889085 | 0.77 | SMN1; SMN2 (0.53) | AKT1HRH4ALDH1A1 | |
| SCHEMBL2075530 | 0.77 | KIT (0.48) | LRRK2HRH3AKT1KDM4EALDH1A1 | |
| SCHEMBL4172255 | 0.75 | GRIN2D (0.49) | HRH3OGAHRH4KDM4EALDH1A1 | |
| SCHEMBL27743649 | 0.75 | LRRK2 (0.42) | LRRK2HRH3OGAHRH4 | |
| SCHEMBL5889086 | 0.74 | MAP4K4 (0.54) | LRRK2PIK3CAMTORKDM4EALDH1A1 | |
| SCHEMBL17623178 | 0.74 | HRH4 (0.51) | LRRK2HRH3AKT1HRH4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2032554-A1 | PIPERIDINYL PYRIMIDINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-03-11 | — | — | EP | claimed |
| WO-2007137955-A1 | PIPERIDINYL PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-06 | — | — | WO | claimed |
| US-20070281921-A1 | Piperidinyl pyrimidine derivatives | HOFFMAN-LA ROCHE INC. | 2007-12-06 | — | — | US | claimed |
| US-7902184-B2 | Piperazinyl pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-03-08 | — | — | US | disclosed |
| EP-2032554-A1 | PIPERIDINYL PYRIMIDINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007137955-A1 | PIPERIDINYL PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-06 | — | — | WO | disclosed |
| US-20070281921-A1 | Piperidinyl pyrimidine derivatives | HOFFMAN-LA ROCHE INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281921-A1 | Piperidinyl pyrimidine derivatives | HRH2, P2RX5, P2RX3 | LRRK2 1721/4885HRH3 8/4885AKT1 2682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.